News Feed

MPN News

MPN rss feedThe MPN News feed provides frequent updates on the latest happenings in the MPN World. Fresh content, with brief summary is automatically updated frequently from reliable sources.  Just click on the red hyperlink to pull up the complete news item.

Make PV Reporter your “starting point” for all MPN related news.

The Lifetime Channel's Behind the Mystery featured a story this week on polycythemia vera, with experts Dr. Richard T. Silver, a professor of medicine at NewYork–Presbyterian/Weill Cornell Medical Center, and Dr. Srdan Verstovsek of the MD Anderson Cancer Center, who discuss the latest inpatient care and clinical trials for PV, [...]
Thu, Sep 13, 2018, Continue reading at the source
Drug development in myeloproliferative neoplasms (MPNs), specifically polycythemia vera (PV) and myelofibrosis, have both remained similar to their diagnosis: difficult, explained Andrew T. Kuykendall, MD. Regarding therapeutic advances, the FDA approved ruxolitinib (Jakafi) for the treatment of patients with myelofibrosis and polycythemia vera in 2011 and 2014, respectively. However, researchers are [...]
Tue, Sep 11, 2018, Continue reading at the source
Treatment of myelofibrosis, a rare type of blood cancer, with Jakafi (ruxolitinib) gives a patient 16 times the risk of developing aggressive B-cell lymphoma, through the activation of a pre-existing “dormant” lymphoma, according to a recent study. The results suggest that the detection of this “dormant” lymphoma may be useful to [...]
Mon, Sep 10, 2018, Continue reading at the source
There was a time when we didn't think young children could have an MPN. We now know MPNs do not discriminate. Infants, children and young adults are being diagnosed regularly. Pediatric MPN specialist Dr. Nicole Kucine, MD, MS, Weill Cornell Medicine, partnered with us to bring attention to this group [...]
Wed, Sep 05, 2018, Continue reading at the source
Getting Pegasys onto the Government's Approved Drug Listing By Nathalie Cook MPN Patient and Advocate Nathalie Cook, works as an Accredited Practicing Dietitian in Community Health in Melbourne In Australia over the last 20 years, myeloproliferative neoplasm (MPN) consumer advocacy has been strong. This began with the tireless support that the late Ian [...]
Tue, Sep 04, 2018, Continue reading at the source
The largest ever study of its type is the first to definitively show an increased risk of blood cancers in relatives of patients. A team led by scientists at The Institute of Cancer Research, London, and the German Cancer Research Centre in Heidelberg have uncovered new evidence, supporting a role for [...]
Tue, Aug 07, 2018, Continue reading at the source
MPN patient advocacy, Nathalie Cook
Brilliant work by Nathalie Cook lobbying the Australian Government for access to affordable drugs for Cancer Patients Inspiring, tenacious and rewarding work that will benefit the lives of so many. Australian MPN patients can now have affordable access to Pegasys. This is the kind of success I would like [...]
Mon, Jul 16, 2018, Continue reading at the source
Publisher's Note: My source at the American Society of Hematology (ASH) informed me that “initially MPNs aren't going to be a primary focus, however, we expect that this project will lead to better understanding of MPNs in the future.” Thanks to the American Society of Hematology for being the source [...]
Mon, Apr 09, 2018, Continue reading at the source
Metformin demonstrates antileukemic activity and may have clinical implications for the treatment of myeloproliferative neoplasms (MPN) in combination with ruxolitinib, according to a study published in Cell Death & Disease. The JAK1/2 inhibitor ruxolitinib demonstrates clinical activity among patients with MPN (eg, essential thrombocythemia, primary myelofibrosis, polycythemia vera), but rarely produces [...]
Fri, Mar 09, 2018, Continue reading at the source
AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE Researchers have discovered how some of the blood cancers known as myeloproliferative neoplasms (MPNs) evade the immune system. Their findings reveal that a subset of MPNs might be susceptible to treatment with immune checkpoint inhibitors that specifically target the PD-1/PD-L1 pathway (a signaling [...]
Thu, Feb 22, 2018, Continue reading at the source
February 29th is Rare Disease Day: 4 Reasons You Should Care Even though MPN patients who have a rare disease many may have never heard of "Rare Disease Day" and know next to nothing about the impact rare disorders have on society. Rare diseases play a larger role in public [...]
Mon, Feb 29, 2016, Continue reading at the source
It's World Cancer Day There has been, from time to time, a question about whether myeloproliferative neoplasms are cancers. Let's be clear, they are. But don't take our word for it. Cancer Support Community defines Myeloproliferative Neoplasms (MPNs) as types of blood cancers that overproduce blood cells in the bone [...]
Mon, Feb 01, 2016, Continue reading at the source
For the past several months we've kept you informed and taking action on Medicare's pending decision of whether to provide coverage for people with myelofibrosis seeking a stem cell transplant. Currently there is no official ruling from Medicare on whether this treatment is covered, leaving many patients to risk paying [...]
Tue, Jan 12, 2016, Continue reading at the source
Each year for the past three years, Cure Magazine and Incyte Corporation have recognized efforts within the MPN community with their MPN Hero award. The two categories are commitment to the community or individual. Past winners have included Ruben Mesa, Zhenya Senyak, Joyce Niblack, Richard Silver, and many more. We [...]
Sun, Dec 27, 2015, Continue reading at the source
According to a paper published in Nature Medicine, the drug MLN8237 (or Alisertib) has reduced tumor cells, blood counts and fibrosis in mouse models of myelofibrosis. Reports John Crispino, PhD, "This new paper shows that Alisertib has an anti-tumor effect in samples of myelofibrosis, similar to what we saw in [...]
Tue, Dec 01, 2015, Continue reading at the source


error: Content is protected !
WordPress Security